Skip to Content

Clinical Trials Detail

A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Objective
This is a clinical trial of investigational drug PF-04449913 which will be administered orally.
IRB Protocol Number
12-1558
Principal Investigator(s)
DAN POLLYEA

Cancer Trials

  • Leukemia/Myelodysplasia
Sponsor(s)
UCCC
Contact
EMILY DENONCOURT at 303-748-0566
or EMILY.DENONCOURT@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period will determine eligibility. The treatment period will consist of 28 day cycles for as long as your doctor determines you are still benefitting from the treatment. The follow- up period will consist of one final visit to the clinic. // Eligibility criteria include but are not limited to 18 years or older with Acute Leukemia and high risk of post-allogeneic stem cell transplantation relapse.